OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Jacob on the Potential Role for TAR-200 in BCG-Unresponsive, High Risk NMIBC

July 31st 2025

Joseph Jacob, MD, MCR, discusses the potential role of an intravesical gemcitabine delivery system for BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Jamroziak on Daratumumab vs Observation in Multiple Myeloma With MRD Reappearance

July 31st 2025

Krzysztof Jamroziak, PhD, discusses findings from the phase 2 PREDATOR-MRD trial (NCT03697655).

Dr Dietrich on the Efficacy and Safety of Taletrectinib in ROS1+ NSCLC

July 31st 2025

Martin F. Dietrich, MD, PhD, discusses the efficacy and safety profiles of taletrectinib for the management of ROS1-positive non–small cell lung cancer.

Dr Richter on the FDA Approval of Linvoseltamab for R/R Multiple Myeloma

July 31st 2025

Joshua Richter, MD, discusses the FDA approval of linvoseltamab for relapsed or refractory multiple myeloma.

Dr Blanco on the Conditional EU Approval of Mirdametinib for NF1-Associated PNs

July 31st 2025

Ignacio Blanco, MD, PhD, discusses the significance of the European approval of mirdametinib for symptomatic, inoperable plexiform neurofibromas.

Dr Hayne on the Rationale for Evaluating Mitomycin Plus BCG vs BCG Alone in NMIBC

July 31st 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the rationale for evaluating the addition of mitomycin to BCG in non–muscle-invasive bladder cancer.

Dr Salgia on Biomarker-Driven Therapies of Interest for Second-Line SCLC

July 30th 2025

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Dr Kim on the Collaborative, Forward-Thinking Nature of the 2025 BTG in Lung Cancer Meeting

July 30th 2025

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Dr Sen on the Role of Immunotherapy in SCLC

July 30th 2025

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Dr Florez on the Importance of Establishing Consensus Within the Evolving Lung Cancer Treatment Landscape

July 30th 2025

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Dr Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLC

July 30th 2025

Gilberto Lopes, MD, MBA, FAMS, discusses findings from a cost-effectiveness analysis of osimertinib/chemotherapy vs amivantamab/lazertinib in EGFR-mutated NSCLC.

Dr Mascarenhas on Key Considerations for Clinical Trial Enrollment in Myelofibrosis

July 29th 2025

John O. Mascarenhas, MD, discusses important factors to consider when evaluating patients for clinical trial enrollment in myelofibrosis.

Dr Huppert on the Implications of SERENA-6 for Second-Line Treatment Strategies in HR+ Breast Cancer

July 29th 2025

Laura A. Huppert, MD, discusses how the approval of the SERENA-6 regimen could affect second-line treatment decision-making in HR-positive breast cancer.

Dr Kamdar on Optimizing Patient Monitoring After Liso-Cel in MCL

July 29th 2025

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer

July 26th 2025

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC

July 26th 2025

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

Dr Landgren on Considerations Surrounding the Current Treatment Paradigm for Smoldering Multiple Myeloma

July 26th 2025

C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.

Dr Danilov on Considerations in Frontline Treatment Selection for CLL

July 26th 2025

Alexey Danilov, MD, PhD, discusses frontline treatment selection for chronic lymphocytic leukemia.

Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLC

July 25th 2025

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Dr Mok on Choosing Between First-Line Therapies for BRAF-Mutant NSCLC

July 25th 2025

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.